Added to YB: 2024-08-16
Pitch date: 2024-06-30
NVO [bullish]
Novo Nordisk A/S
-73.23%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 137.00
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
growth
Loomis Sayles International Growth Fund Portfolio Holding: Novo Nordisk A/S
NVO: Global leader in diabetes/obesity w/ 90% sales. 33% diabetes & 85% obesity market share. Q3 beat, FY guidance up 1%. GLP-1s (Wegovy/Ozempic) driving growth. 100M+ US obese patients. 40%+ new patient share. Double-digit rev/FCF growth expected. Shares undervalued despite Lilly competition. Ongoing innovation & execution key to long-term success.
Read full article (3 min)